Fedorak RN - Search Results

1

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

Huang VW, Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN. Huang VW, et al. Among authors: fedorak rn, fedorak dk. Inflamm Bowel Dis. 2015 Jun;21(6):1359-67. doi: 10.1097/MIB.0000000000000376. Inflamm Bowel Dis. 2015. PMID: 25989340 Free PMC article.

2

Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.

Sample C, Bailey RJ, Todoruk D, Sadowski D, Gramlich L, Milan M, Cherry R, Ma M, Lalor E, McKaigney J, Sherbaniuk R, Matic K, Switzer C, Fedorak RN. Sample C, et al. Among authors: fedorak rn. Can J Gastroenterol. 2002 Mar;16(3):165-70. doi: 10.1155/2002/379307. Can J Gastroenterol. 2002. PMID: 11930194

3

Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease.

Patel B, Schutte R, Sporns P, Doyle J, Jewel L, Fedorak RN. Patel B, et al. Among authors: fedorak rn. Inflamm Bowel Dis. 2002 Sep;8(5):340-6. doi: 10.1097/00054725-200209000-00005. Inflamm Bowel Dis. 2002. PMID: 12479649

4

Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs.

Sydora BC, Tavernini MM, Wessler A, Jewell LD, Fedorak RN. Sydora BC, et al. Among authors: fedorak rn. Inflamm Bowel Dis. 2003 Mar;9(2):87-97. doi: 10.1097/00054725-200303000-00002. Inflamm Bowel Dis. 2003. PMID: 12769442

5

Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease.

Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Seinhart H, Greenberg G. Siffledeen JS, et al. Among authors: fedorak rn. Inflamm Bowel Dis. 2004 May;10(3):220-8. doi: 10.1097/00054725-200405000-00007. Inflamm Bowel Dis. 2004. PMID: 15290915

6

Probiotics and the management of inflammatory bowel disease.

Fedorak RN, Madsen KL. Fedorak RN, et al. Inflamm Bowel Dis. 2004 May;10(3):286-99. doi: 10.1097/00054725-200405000-00018. Inflamm Bowel Dis. 2004. PMID: 15290926 Review.

7

Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events.

Sayani FA, Prosser C, Bailey RJ, Jacobs P, Fedorak RN. Sayani FA, et al. Among authors: fedorak rn. Can J Gastroenterol. 2005 Mar;19(3):147-51. doi: 10.1155/2005/470863. Can J Gastroenterol. 2005. PMID: 15776134 Clinical Trial.

8

Postoperative Crohn's disease.

Penner RM, Madsen KL, Fedorak RN. Penner RM, et al. Among authors: fedorak rn. Inflamm Bowel Dis. 2005 Aug;11(8):765-77. doi: 10.1097/01.mib.0000171273.09757.f2. Inflamm Bowel Dis. 2005. PMID: 16043993 Review.

9

Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury.

Sydora BC, Martin SM, Lupicki M, Dieleman LA, Doyle J, Walker JW, Fedorak RN. Sydora BC, et al. Among authors: fedorak rn. Inflamm Bowel Dis. 2006 Jun;12(6):429-36. doi: 10.1097/00054725-200606000-00001. Inflamm Bowel Dis. 2006. PMID: 16775486

10

A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor-alpha gene-deficient mice.

Sydora BC, Tavernini MM, Doyle J, Fedorak RN. Sydora BC, et al. Among authors: fedorak rn. Inflamm Bowel Dis. 2006 Aug;12(8):750-7. doi: 10.1097/00054725-200608000-00012. Inflamm Bowel Dis. 2006. PMID: 16917231

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

280 results

Search Page

Filters